Table TDI-3. Trend of new clients entering treatment by primary drug used, 1993 to 2006 [see all tables in this series...]

Part (iii) Percentage of new clients using stimulants (amphetamines and MDMA)

Country		1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006
Belgium		1.4	4.2	6.1	5.5	6.4	3.4
Bulgaria			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.9	1.5	2.0	2.7
Czech Republic				41.2	43.2	48.8	56.8	52.8	46.0	47.8	55.0	55.6	59.0	60.1	61.7
Denmark								11.0	7.0		10.3	12.7	14.2	11.2	16.8
Germany									10.2	11.4	10.0	10.2	9.4	9.4	10.0
Ireland		4.9	3.3	8.0	6.3	7.0	4.8	5.7	6.5	9.9	8.6	8.0	6.7	5.7	9.9
Greece			0.0	0.2	0.0	0.3	0.0	0.2	0.3	0.4	0.7	0.6	0.7	0.1	0.4
Spain					1.1	1.1	2.3	2.1	2.7	3.0	3.7		1.7	1.9
France						1.8		1.6				2.1		1.2	0.9
Italy		0.2	0.3	0.3	0.4	0.6	0.9	1.1	1.0	1.0	1.0	1.0	1.0	0.9	0.6
Cyprus										6.1	6.0	6.2	5.3	1.4	3.1
Latvia											11.3	15.1	26.8	23.8	27.9
Lithuania											3.0	4.8	2.4	0.0	4.3
Luxembourg	(1)			0.0	4.0	2.0	3.0	2.0	1.0	1.0	0.0	0.0	2.5	0.4	2.4
Hungary	(2)				7.1	12.2	14.0	10.7	7.5	7.0	6.3	8.2	7.9	11.0	9.6
Malta	(3)				0.8	0.4						1.2	0.0	1.6	5.0
Netherlands			3.5	7.2	10.3	9.5	8.1	6.7	4.8	4.1	5.6	7.0	8.3	9.1	9.5
Austria	(4)		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.5
Poland	(5)					3.8	6.0	6.7	5.8	6.0	8.1	11.9
Portugal								0.0	0.0			0.8	0.5	0.2	0.4
Romania										0.3	0.5	1.0	1.0	1.8	0.8
Slovenia	(6)					0.2		0.7			1.0	1.0	1.1
Slovakia			1.7	1.2	2.0	2.6	3.2	2.3	6.8	7.8	15.1	25.4	32.1	30.4	32.6
Finland							41.1	41.9	30.8	30.0	33.9	33.9	30.9	26.3	24
Sweden									28.7	32.3	34.2	32.1	28.6	25.6	27.1
United Kingdom	(7)	11.0	9.0	10.0	9.0	9.0	9.0	8.0	4.0	3.0	3.0	6.0	7.0	5.6	5.0
Turkey													7.5	7.3	4.2

Notes:

 (1) Data refer to all treatments.  

 (2) Data refer to all treatments. For 2004 data refer to first treatments.  

 (3) In order to include time trends, data reported in Table 3 refer to one outpatient centre for which data were available for the whole time period. 

 (4) In the case of Austria, up to 2005 data only refer to clients in substitution treatment, using opioids as a primary drug. Since 2006, new data collection has been conducted. 

 (5) Data refer to all treatments up to 2002. For 2003 data refer to first treatments. Heroin includes all opiates. For 2004–06, data were not available and therefore not included in the analysis. 

 (6) Data for 2004 includes data for outpatient clients and clients treated in prison. Data for outpatient clients was validated, however data collection for prison clients was still in the process of development, thus figures are underestimated.With effect from next year the process of data validation for prison clients will be implemented. 

 (7) Data refer to all treatments up to 2002 and to new treatments from 2003. Before 2003, data only refer to amphetamines. 

 See also ‘General notes for interpreting data’ on the Explanatory notes and help page. 

Sources:

 Reitox national reports 2007 — Standard table 3 and TDI 

• Download this data in Excel (.xls) format

(see the help page for information about formats etc.)